PubMed COVID-19 Clinical Care

CONCLUSIONS: TheraPPP will evaluate the effectiveness and implementation of an HRF and ARDS care pathway.

CONCLUSIONS: TheraPPP will evaluate the effectiveness and implementation of an HRF and ARDS care pathway.

BACKGROUND AND OBJECTIVES: At least 15% of patients who recover from acute severe acute respiratory syndrome coronavirus 2 infection experience lasting symptoms ("Long-COVID") including "brain fog" and deficits in declarative memory. It is not known

CONCLUSIONS: We found limited evidence of successful adaptation of school health and nutrition programme implementation during the pandemic, especially from Asia and Africa. While the adoption of the World Health Organization health-promoting school

Long Covid is a debilitating condition of unknown etiology. We performed multimodal proteomics analyses of blood serum from COVID-19 patients followed up to 12 months after confirmed severe acute respiratory syndrome coronavirus 2 infection. Analysis

CONCLUSIONS: TheraPPP will evaluate the effectiveness and implementation of an HRF and ARDS care pathway.

CONCLUSIONS: TheraPPP will evaluate the effectiveness and implementation of an HRF and ARDS care pathway.

CONCLUSIONS: TheraPPP will evaluate the effectiveness and implementation of an HRF and ARDS care pathway.

CONCLUSIONS: TheraPPP will evaluate the effectiveness and implementation of an HRF and ARDS care pathway.

CONCLUSIONS: TheraPPP will evaluate the effectiveness and implementation of an HRF and ARDS care pathway.